Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-08-09

Clinical Trial Update: Efficacy and Safety Trial of Rimegepant for Migraine Prevention in Adults [Phase 2, Phase 3]

View source ↗

Summary

Pfizer completed Phase 2 and Phase 3 trials evaluating rimegepant for migraine prevention in adults, with results posted in August 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Rimegepant (rimegepant)

Snippet

Sponsor: Pfizer | Conditions: Migraine | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2021-08-09